OncoMatch/Clinical Trials/NCT06392009
Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II
Is NCT06392009 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Radiprodil for tuberous sclerosis complex.
Treatment: Radiprodil — Study RAD-GRIN-201 is a phase 1B/2A trial to assess safety, tolerability, pharmacokinetics (PK), and potential efficacy of radiprodil in participants with Tuberous Sclerosis Complex (TSC) or Focal Cortical Dysplasia (FCD) type II. The study is open-label, so all participants will be treated with radiprodil. Subjects' participation in the study is expected to last up to six months in Part A and one year in Part B/long-term treatment period. The treatment period in Part B may be extended based on a favorable benefit/risk profile.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Must have received: anti-seizure medication
Lab requirements
Liver function
Severe hepatic dysfunction (Child-Pugh grade C) excluded
Severe hepatic dysfunction (Child-Pugh grade C).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify